Hepatocellular carcinoma: tumor heterogeneity and recurrence after preoperative locoregional therapy
- 26 October 2023
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 40 (12) , 1-8
Abstract
How locoregional therapy (LRT) may change tumor compositional and functional heterogeneity, consequently contributing to treatment resistance and tumor recurrence remains largely unknown. A series of hepatocellular carcinomas (HCCs) treated with preoperative locoregional therapy (LRT) that relapsed after surgery was studied. Thirty HCCs comprising 15 patients treated with LRT prior to liver transplantation (n = 14)/surgical resection (n = 1) were studied. Five patients undergoing pre-transplant LRT, comprising 11 HCCs, presented tumor recurrence (median recurrence time = 10 months). Clinicopathological data and immunoexpression of proliferation markers (Ki67, p53), cholangiocytic/hepatic progenitor cell (HPC) markers (EpCAM)/BerEp4, CK19, CK7) and mesenchymal markers (ASMA, vimentin) were evaluated in tumoral epithelial/stromal cells and in peritumoral parenchyma. Higher grading of tumor differentiation, microvascular invasion and tumoral cell p53 expression significantly associated with recurrence (p < 0.05). Piecemeal necrosis features were more frequent in tumors that recurred (p < 0,05). Tumoral and peritumoral Ki67 expression and EpCAM, CK19 and CK7 expression in tumoral cells tended to be higher in treated tumors that recurred. Peritumoral expression of cholangiocytic/HPC markers and tumoral epithelial and stromal cellular expression of mesenchymal markers tended to be higher for tumors without recurrence. Recurrence after transplant with preoperative LRT might be associated with poor HCC differentiation, higher cellular proliferation rate, peritumoral piecemeal necrosis features and cholangiocytic/HPC phenotypes. Understanding HCC progression factors after LRT might be important for optimizing patient selection for treatment, improving surveillance after LRT and to explore synergies between LRT and systemic targeted therapies to prevent recurrence.Keywords
Funding Information
- ROCHE/APEF (2014 ROCHE-APEF research grant)
This publication has 17 references indexed in Scilit:
- Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approachesNature Reviews Gastroenterology & Hepatology, 2017
- Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolizationLaboratory Investigation, 2016
- Hypoxia after transarterial chemoembolization may trigger a progenitor cell phenotype in hepatocellular carcinomaHistopathology, 2014
- Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinomaHepatology, 2013
- Prognostic significance of the worst grade in hepatocellular carcinoma with heterogeneous histologic grades of differentiationJournal of Gastroenterology and Hepatology, 2013
- High CD44s expression is associated with the EMT expression profile and intrahepatic dissemination of hepatocellular carcinoma after local ablation therapyJournal of Hepato-Biliary-Pancreatic Sciences, 2012
- Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapyPathology - Research and Practice, 2012
- Expression of Keratin 19 Is Related to High Recurrence of Hepatocellular Carcinoma after Radiofrequency AblationOncology, 2011
- Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantationLiver Transplantation, 2011
- Biliary phenotype of hepatocellular carcinoma after preoperative transcatheter arterial chemoembolizationJournal of Gastroenterology and Hepatology, 2008